Evidence mapPaperPMID 40747214Full record

ReviewWorld journal of hepatology2025

Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.

Bryan Adrian Priego-Parra, Berenice M Román-Calleja, Rocio Gallego-Duran, Jordi Gracia-Sancho, Jose Antonio Velarde Ruiz-Velasco, Jose Maria Remes-Troche

Abstract readReview
In one paragraph

Review in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bryan Adrian Priego-ParraDepartment of Digestive Physiology and Gastrointestinal Motility, Institute of Medical-Biological Research, Universidad Veracruzana, Veracruz 91700, Mexico.
Berenice M Román-CallejaDepartment of Gastroenterology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City 14080, Mexico.
Rocio Gallego-DuranSeLiver Group, Institute of Biomedicine of Seville/CSIC/Hospital Virgen del Rocio, Sevilla 41013, Spain.
Jordi Gracia-SanchoLiver Vascular Biology Research Group, Biomedical Network Research Centers-CIBEREHD, IDIBAPS Research Institute, Barcelona 08036, Catalonia, Spain.
Jose Antonio Velarde Ruiz-VelascoDepartment of Gastroenterology, Hospital Civil of Guadalajara "Fray Antonio Alcalde", Guadalajara 44340, Jalisco, Mexico.
Jose Maria Remes-TrocheDepartment of Digestive Physiology and Gastrointestinal Motility, Institute of Medical-Biological Research, Universidad Veracruzana, Veracruz 91700, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for reliable biomarkers to predict metabolic dysfunction-associated steatotic liver disease (MASLD) remains a key research focus. Traditional anthropometric parameters, such as triglycerides, glucose, and waist circumference (WC), have proven to be robust tools for diagnosing, stratifying, and predicting health outcomes. These measures facilitate early detection, personalized treatment strategies, and long-term risk assessment in metabolic health. The triglyceride-glucose (TyG) index and related parameters, particularly the TyG-WC index, are gaining recognition as reliable biomarkers for MASLD, with consistently high diagnostic accuracy across diverse populations. The TyG-WC index is associated with MASLD and an increased likelihood of all-cause, cardiovascular, and diabetes-related mortality, highlighting its importance in stratification and patient management. This opinion review summarizes key findings on the TyG-WC index across different MASLD populations and provides nutritional recommendations aimed at reducing this index. The TyG-WC index stands out as a practical and scalable biomarker for identifying and stratifying the risk of MASLD, particularly in resource-limited environments where access to advanced diagnostic tools is restricted. However, before the TyG-WC index can be integrated into routine clinical practice, rigorous, longitudinal studies involving ethnically diverse cohorts must validate its prognostic performance. It should be viewed as a complementary tool within a comprehensive metabolic risk assessment framework, supporting preventive strategies while awaiting formal endorsement in clinical guidelines.

Indexed as

BiomarkersCardiometabolic riskLiver steatosisNon-invasiveNutritional therapySteatotic liver disease

Identifiers

PMID40747214
PMCPMC12308583

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.